Subscribe to Updates in Healthcare

RSS By Email

RSS By RSS

Add to Google Reader or Homepage

Subscribe in Bloglines


The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

GLG News by Ophthalmologists

Articles with lock require a subscription to GLG News | Request a free trial
February 18, 2008
New promising glaucoma agent for glaucoma treatment
Analysis of: Biovitrum has Completed an Exploratory Clinical Phase II Study in Glaucoma | www.pipelinereview.com
Author: GLG Expert Contributor
1. glaucoma treatment 2. combined therapy 3. IOP reduction
Barry SchechterJanuary 29, 2008
Bausch makes foray into presbyopic arena
Analysis of: Bausch & Lomb announces acquisition of eyeonics | www.osnsupersite.com
Author: Barry Schechter, Director of Corneal and External Diseases, Florida Eye Microsurgical Institute, Inc.
With the recent trends of presbyopic correction , Bausch and Lomb has now entered the arena.
January 28, 2008
A MATCH MADE IN HEAVEN.
Analysis of: Bausch & Lomb announces acquisition of eyeonics | www.osnsupersite.com
Author: GLG Expert Contributor
I HAVE BEEN PRODICTING THAT A MAJOR PLAYER WOULD BUY EYEONICS SINCE I FIRST STARTED PLACING THE CRYSTALENS IN MY PATIENTS. THE LENS WORKS BUT NEEDED A PRO AT MARKETING. B& L WILL BENIFIT FROM THIS BUY.
January 28, 2008
NO SURPRISE.
Analysis of: 19 Percent of Office-Based Physicians Refuse to See Pharmaceutical, Biotech and Medical Device Sales Reps | www.drugs.com
Author: GLG Expert Contributor
MOST TEACHING HOSPITALS LOOK DOWN THEIR ACADEMIC NOSE AT ANYTHING COMMERICAL. THESE SAME SCHOOLS DON'T TEACH DOCTORS HOW TO SURVIVE MUCH LESS SUCEED IN THE PRIVATE SECTOR.
January 23, 2008
Benefits of TELESCOPIC lens implants important for those already effected by macular degeneration
Analysis of: Telescopic IOL device shows potential for improving quality of life in AMD patients | www.osnsupersite.com
Author: GLG Expert Contributor
As ophthalmologists, we have been waiting for development of a useful telescopic intraocular lens implant for over 17 years. These lenses have been in FDA trials for years, but never brought to market because of numerous problems with them. A viable telescopic lens implant would give us something to...
Robert DevenyiDecember 6, 2007
Genentech enrages vitreoretinal specialists
Analysis of: Genentech to cease supplying bevacizumab to compounding pharmacies | www.osnsupersite.com
Author: Robert Devenyi, Professor and Chief of Ophthalmology, University of Toronto
-Retinal community unites against Genentech -both the American Association of Ophthalmology and the American Society of Retinal Specialists have condemned Genentech's actions -this represents profit-driven pharma at their worst -very poor decision by Genentech...not only to galvanize the profession...
November 9, 2007
COMBIGAN (AGN) will not add much to the Lucrative Glaucoma Market.
Analysis of: Allergan, Inc. Receives FDA Approval For COMBIGAN™ (Brimonidine Tartrate/timolol Maleate Ophthalmic Solution) 0.2%/0.5% | www.medicalnewstoday.com
Author: GLG Expert Contributor
Combigan is a glaucoma medication which combines a beta blocker and alpha agonist. Although combination drugs are great for glaucoma management, this will NOT be a first line medication in treating glaucoma.  The prostaglandins (PFE, ACL) are still the gold standard IOP lowering agents...
November 8, 2007
U.S. Ophthalmologists Still Waiting for Prostaglandin/Timolol Combo
Analysis of: Allergan, Inc. Receives FDA Approval For COMBIGAN™ (Brimonidine Tartrate/timolol Maleate Ophthalmic Solution) 0.2%/0.5% | www.medicalnewstoday.com
Author: GLG Expert Contributor
The market for eye drops for the treatment of open angle glaucoma is huge. Profit potential for pharmaceutical companies, however, is limited by the time period that they are afforded patent protection. Combigan, the just approved brimonidine/timolol combination therapy, affords Allergan new patent...
November 6, 2007
New Glaucoma Product Should Simplify Patient Compliance and Increase Allergan's Share of Glaucoma Market
Analysis of: Allergan, Inc. Receives FDA Approval For COMBIGAN™ (Brimonidine Tartrate/timolol Maleate Ophthalmic Solution) 0.2%/0.5% | www.medicalnewstoday.com
Author: GLG Expert Contributor
Patient compliance with glaucoma eyedrops is a key barrier in achieveing acceptable clinical outcomes. There is only one other product, Cosopt (by Merck) that offers a combination glaucoma medication. This medication may become a popular choice for glaucoma doctors to improve patient complian...
October 31, 2007
GENETECH BACKTRACKS ON ITS DECISION TO LIMIT AVASTIN FOR WET MACULAR DEGERNATION
Analysis of: Genentech revisits plan for Avastin | www.sfgate.com
Author: GLG Expert Contributor
In the two weeks since Genetech made its announcement that it would limit the availability of Avastin to ophthalmologists for use in treating wet macular degeneration the outcry from patients, ophthalmologists, politicians, and the American Academy of OPhthalmology has been so great that Genetech is...

Previous Page : 1 2 3 4 5 6 7 8 9 10 11 12 13 Next31 to 40 of 158

More GLG News in
Healthcare

Most Popular:
Source Article | Expert Analyses
 

GLG News: What Experts Think Is Important





Analytics


Generated at 2008-12-01T21:45:56.203